Table 2.
Vaccine under various phases: I/II, II and III (as of July 2020).
| Phase | Name | Developer | Type | Design, Product Description | Location | Start date |
|---|---|---|---|---|---|---|
| Phase III | Moderna mRNA-1273 | Moderna/NIAID | RNA | Double-blind, mRNA-1273, encodes for a form of the spike (S) protein on the virus | USA | 27/07/2020 |
| Phase III | Sinovac vaccine | Ege University | Inactivated | Double-blind, Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc) | Brazil | 01/07/2020 |
| Phase II/III | Oxford AZD1222/ChAdOx1-S | Immunomic Therapeutics/EpiVax/PharmaJet | Non-replicating viral vector | Single-blind, Non-replicating viral vector; AZD 1222 (formerly ChAdOx1) | UK | 28/05/2020 |
| Phase II | AZLB protein subunit vaccine | Protein subunit | Double-blind | China | 12/07/2020 | |
| Phase II | Cansino Ad5-nCoV | Non-replicating viral vector | Double-blind | China | 12/04/2020 | |
| Phase II | Moderna mRNA-1273 | Symvivo | RNA | Observer-blind, doseconfirmation, RNA; LNPencapsulated mRNA (mRNA 1273) | USA | 29/05/2020 |
| Phase I/II | Aivita AV-COVID-19 | Other | Double-blind, dose-finding | USA | 01/07/2020 | |
| Phase I/II | Altimmune T-COVID | Non-replicating viral vector | TBC | TBC | 01/06/2020 | |
| Phase I/II | Bharat Covaxin | Inactivated | Double-blind | India | 13/07/2020 | |
| Phase I/II | BIBP/Sinopharm BBIBP-CorV | BioNet Asia | Inactivated | Double-blind, dose-finding, Inactivated | China | 28/04/2020 |
| Phase I/II | BioNTech BNT162 | Takis/Applied DNA Sciences/Evvivax | RNA | 3 LNP-mRNAs; BNT162 | USA | 29/04/2020 |
| Phase I/II | BioNTech BNT162 | RNA | Open-label, dose-finding | Germany | 23/04/2020 | |
| Phase I/II | CAMS vaccine | Chula Vaccine Research Center | Inactivated | Double-blind, dose-finding, Inactivated | China | 15/05/2020 |
| Phase I/II | Cansino Ad5-nCoV | Mediphage Bioceuticals/University of Waterloo | Non-replicating viral vector | Double-blind, dose-finding, Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV) | Canada | 01/08/2020 |
| Phase I/II | Genexine GX-19 | Genexine Consortium (GenNBio, International Vaccine Institute, (KAIST), (POSTECH)/Binex | DNA | Double-blind | South Korea | 17/06/2020 |
| Phase I/II | Inovio INO-4800 | DNA | Open-label (A), double-blind (B), dose-finding | South Korea | 22/06/2020 | |
| Phase I/II | Sinovac vaccine | Inactivated | Double-blind, dose-finding | China | 16/04/2020 | |
| Phase I/II | Sinovac vaccine | Inactivated | Double-blind, dose-finding | China | 20/05/2020 | |
| Phase I/II | WIBP vaccine | Entos Pharmaceuticals/Cytiva | Inactivated | Double-blind, dose-finding, Inactivated | China | 11/04/2020 |
| Phase I/II | Zydus Cadila DNA vaccine | DNA | Double-blind | India | 13/07/2020 |